GB807781A - Plasma fraction and standard plasma preparation and method of preparing same - Google Patents

Plasma fraction and standard plasma preparation and method of preparing same

Info

Publication number
GB807781A
GB807781A GB13545/55A GB1354555A GB807781A GB 807781 A GB807781 A GB 807781A GB 13545/55 A GB13545/55 A GB 13545/55A GB 1354555 A GB1354555 A GB 1354555A GB 807781 A GB807781 A GB 807781A
Authority
GB
United Kingdom
Prior art keywords
plasma
per cent
sodium
solution
bovine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB13545/55A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of GB807781A publication Critical patent/GB807781A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21006Coagulation factor Xa (3.4.21.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A plasma fraction capable of increasing the activity of thromboplastic material having a prothrombin time of more than 9 seconds is prepared at a low temperature, e.g. - 5 DEG to 5 DEG C., by adding 3 to 5 volumes of a 15 to 30 per cent by volume aqueous solution of methanol, ethanol or a mixture thereof, e.g. at - 5 DEG to - 10 DEG C., at a pH of 4 to 5, to prothrombin-free horse, bovine, human or rabbit plasma, e.g. at 5 DEG to 0 DEG C., stirring and centrifuging the mixture and adding to the separated residue, e.g. at 0 DEG to - 5 DEG C., 3 to 5 volumes of a 5 to 20 per cent aqueous solution of methanol, ethanol or a mixture thereof, e.g. at 0 DEG to - 5 DEG C., at a pH of 6 to 8, containing 4 to 6 per cent by weight of an alkali metal salt of an amino acid having not more than 6 carbon atoms, e.g. alumina, glycine, proline, serine, stirring and centrifuging the mixture, e.g. at 0 DEG to - 5 DEG C., dialyzing the filtered supernatant against distilled water, e.g. at 1 DEG to 5 DEG C., and lyophilizing the supernatant. A standard plasma preparation for use in the determination of the prothrombin time of thromboplastic material is prepared by dissolving 2 to 10 mg. of the plasma fraction per mol. of oxalated bovine plasma. The prothrombin free plasma may be prepared by centrifuging a solution of the plasma in a heparin sodium solution which has been slurried with 2 to 5 per cent barium sulphate. The oxalated bovine plasma is prepared by centrifuging a solution of bovine blood containing 10 per cent by volume of 0.1 molar sodium oxalate solution. The oxalated bovine plasma may be diluted with 0.85 per cent aqueous sodium chloride solution such that the plasma is present in an amount of 60 to 90 per cent by volume of the diluted plasma. The pH may be adjusted by addition of an alkali metal hydroxide, and buffered using a sodium acetate-acetic acid, sodium succinate-succinic acid, sodium acid phthalate-phthalic acid, mono- or di-sodium phthalate buffer. Specification 807,782 is referred to.
GB13545/55A 1954-05-27 1955-05-10 Plasma fraction and standard plasma preparation and method of preparing same Expired GB807781A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US807781XA 1954-05-27 1954-05-27

Publications (1)

Publication Number Publication Date
GB807781A true GB807781A (en) 1959-01-21

Family

ID=22159560

Family Applications (1)

Application Number Title Priority Date Filing Date
GB13545/55A Expired GB807781A (en) 1954-05-27 1955-05-10 Plasma fraction and standard plasma preparation and method of preparing same

Country Status (1)

Country Link
GB (1) GB807781A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11740019B2 (en) 2019-03-14 2023-08-29 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11747082B2 (en) 2019-03-14 2023-09-05 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11815311B2 (en) 2019-03-14 2023-11-14 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11994343B2 (en) 2019-03-14 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Similar Documents

Publication Publication Date Title
ANTONIADES et al. Studies on the state of insulin in blood:“free” insulin and insulin complexes in human sera and their in vitro biological properties
Lindley A study of the kinetics of the reaction between thiol compounds and chloroacetamide
ES444558A1 (en) Production of long acting insulin preparations
GB807781A (en) Plasma fraction and standard plasma preparation and method of preparing same
GB824908A (en) Improvements in or relating to triazine derivatives
GB980227A (en) Purification and/or concentration of material containing interferon
GB1372812A (en) Cerebrospinal fluid control standard
GB1491816A (en) Urokinase production
GB748024A (en) Improved therapeutic preparations of iron
GB807782A (en) Thromboplastin and thromboplastic compositions and method of preparation thereof
US2574889A (en) Methylated gelatin-insulin preparation
ES357848A1 (en) Stable poliomyelitis vaccines
GB889769A (en) Slowly acting insulin preparation in crystalline form
GB748857A (en) Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB901675A (en) Process for improving the storage qualities of conserved whole-blood
ES448571A1 (en) Stable clumping factor for the identification of fibrinogen and fibrin cleavage products and process for preparing it
US2364579A (en) Hog cholera vaccine
Schmoyer et al. Cystic fibrosis: Effect of media from cultured cystic fibrosis fibroblasts on ATPase activity
GB613080A (en) Improvements in the preparation of stable medicinal salts of acetylsalicylic acid
BR8901329A (en) REACTIVE DERIVATIVES OF ZIRCONIUM AND PROCESS FOR ITS PREPARATION
GB768639A (en) Method for ensilage of grass and green fodder
Franklin et al. Biochemical studies with a new cytotoxic immunosuppressive agent, 3-acetyl-5-(4-fluorobenzylidene)-2, 5-dihydro-4-hydroxy-2-oxothiophen (ICI 47776)
GB887012A (en) Process for the preparation of 18ª--glycyrrhetinic acid
Schwab et al. Reactions of monkeys to experimental respiratory infections. II. Response to streptococcus hemolyticus group c
GB747315A (en) Improvements in or relating to injectable adrenocorticotrophin preparation